B7-2/CD86 Antibody (BU63), Novus Biologicals™

B7-2/CD86

Monoclonal

0.2 mg/ml

Western Blot 0.5-1ug/ml, Flow Cytometry 1-2 ug/million cells, Immunohistochemistry 0.5-1ug/ml, Immunocytochemistry/Immunofluorescence 1-2 ug/ml, Immunohistochemistry-Paraffin 2-4 ug/ml, Immunohistochemistry-Frozen, Knockout Validated

Activation B7-2 antigen, B70, B7-2, B7-2 antigen, B-lymphocyte activation antigen B7-2, BU63, CD28 antigen ligand 2, CD28LG2B7-2 antigen), CD86 antigen, CD86 molecule, CTLA-4 counter-receptor B7.2, FUN-1, LAB72, MGC34413, T-lymphocyte activation antigen CD86

Mouse

70 kDa

0.1 mg

Adaptive Immunity, Cell Cycle and Replication, Dendritic Cell Markers, Diabetes Research, Immunology

942

Human, Mouse, Rat

Purified

Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen), Immunoassay

BU63

Unconjugated

NP_001193853

CD86

ARH-77 (B-lymphoblastoid cell line)

Protein A or G purified

RUO

Primary

Recognizes a protein of 70kDa, which is identified as CD86 (HLDA V; WS Code BP BP072. HLDA V; WS Code A A109. HLDA VI; WS Code BP 95. HLDA VI; WS Code B CD86.9). CD86 is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily of cell surface receptors. It is expressed at high levels on resting peripheral monocytes and dendritic cells and at very low density on resting B and T lymphocytes. CD86 expression is rapidly upregulated by B cell specific stimuli with peak expression at 18 to 42 hours after stimulation. CD86, along with CD80/B71, is an important accessory molecule in T cell co-stimulation via its interaction with CD28 and CD152/CTLA4. Since CD86 has rapid kinetics of induction, it is believed to be the major CD28 ligand expressed early in the immune response. It is also found on malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease.

Store at 4C.

IgG1 κ